Martin Mary Ellen, Milne Thomas A, Bloyer Sebastien, Galoian Karine, Shen Weiping, Gibbs Denise, Brock Hugh W, Slany Robert, Hess Jay L
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Cancer Cell. 2003 Sep;4(3):197-207. doi: 10.1016/s1535-6108(03)00214-9.
MLL fusion proteins are leukemogenic, but their mechanism is unclear. Induced dimerization of a truncated MLL immortalizes bone marrow and imposes a reversible block on myeloid differentiation associated with upregulation of Hox a7, a9, and Meis1. Both dimerized MLL and exon-duplicated MLL are potent transcriptional activators, suggesting a link between dimerization and partial tandem duplication of DNA binding domains of MLL. Dimerized MLL binds with higher affinity than undimerized MLL to a CpG island within the Hox a9 locus. However, MLL-AF9 is not dimerized in vivo. The data support a model in which either MLL dimerization/exon duplication or fusion to a transcriptional activator results in Hox gene upregulation and ultimately transformation.
MLL融合蛋白具有致白血病性,但其机制尚不清楚。截短的MLL的诱导二聚化使骨髓永生化,并对与Hox a7、a9和Meis1上调相关的髓系分化施加可逆阻滞。二聚化的MLL和外显子重复的MLL都是有效的转录激活因子,这表明MLL的二聚化与DNA结合域的部分串联重复之间存在联系。二聚化的MLL比未二聚化的MLL以更高的亲和力结合到Hox a9基因座内的一个CpG岛。然而,MLL-AF9在体内不会二聚化。这些数据支持一种模型,即MLL二聚化/外显子重复或与转录激活因子融合导致Hox基因上调并最终发生转化。